## Petra Reinke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4571291/publications.pdf

Version: 2024-02-01

314 papers 16,359 citations

64 h-index 22102 113 g-index

327 all docs

327 docs citations

times ranked

327

16456 citing authors

#	Article	IF	CITATIONS
1	Monocyte deactivation in septic patients: Restoration by IFN- $\hat{I}^3$ treatment. Nature Medicine, 1997, 3, 678-681.	15.2	1,120
2	Granulocyte–Macrophage Colony-stimulating Factor to Reverse Sepsis-associated Immunosuppression. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 640-648.	2.5	540
3	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncology, The, 2012, 13, 196-206.	5.1	349
4	Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology, 2004, 40, 1421-1425.	3.6	341
5	Protection from cytomegalovirus after transplantation is correlated with immediate early 1–specific CD8 T cells. Journal of Experimental Medicine, 2005, 201, 1031-1036.	4.2	336
6	Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet, The, 2011, 377, 837-847.	6.3	326
7	Anti-Human Leukocyte Antigen and Donor-Specific Antibodies Detected by Luminex Posttransplant Serve as Biomarkers for Chronic Rejection of Renal Allografts. Transplantation, 2009, 87, 1505-1513.	0.5	313
8	Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. Trends in Molecular Medicine, 2019, 25, 149-163.	3.5	288
9	High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nature Medicine, 2019, 25, 242-248.	15.2	280
10	T-cell epitope mapping by flow cytometry. Nature Medicine, 1998, 4, 975-978.	15.2	273
11	Cytomegalovirus (CMV) Phosphoprotein 65 Makes a Large Contribution to Shaping the T Cell Repertoire in CMVâ€Exposed Individuals. Journal of Infectious Diseases, 2002, 185, 1709-1716.	1.9	260
12	Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. European Journal of Immunology, 2000, 30, 1676-1682.	1.6	255
13	Terminally Differentiated CD8 <sup>+</sup> T Cells Negatively Affect Bone Regeneration in Humans. Science Translational Medicine, 2013, 5, 177ra36.	5.8	250
14	Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs). Blood, 2006, 108, 2942-2949.	0.6	241
15	Effect of Anti-CD 20 Antibody Rituximab in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD). American Journal of Transplantation, 2005, 5, 2901-2906.	2.6	237
16	Monitoring Temporary Immunodepression by Flow Cytometric Measurement of Monocytic HLA-DR Expression: A Multicenter Standardized Study. Clinical Chemistry, 2005, 51, 2341-2347.	1.5	224
17	Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrology Dialysis Transplantation, 2009, 24, 1901-1908.	0.4	207
18	Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet, The, 1994, 344, 1737-1738.	6.3	192

#	Article	IF	CITATIONS
19	Antibodies to $\hat{l}^2$ adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain, Behavior, and Immunity, 2016, 52, 32-39.	2.0	188
20	CYTOMEGALOVIRUS INFECTION IN TRANSPLANT RECIPIENTS THE ROLE OF TUMOR NECROSIS FACTOR. Transplantation, 1994, 58, 675-680.	0.5	173
21	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. Journal of Clinical Oncology, 2017, 35, 536-543.	0.8	168
22	Inhibition of ischemia/reperfusion injury and chronic graft deterioration by a single-donor treatment with cobalt-protoporphyrin for the induction of heme oxygenase-1. Transplantation, 2002, 74, 591-598.	0.5	162
23	Up-regulation of HIF in experimental acute renal failure: Evidence for a protective transcriptional response to hypoxia. Kidney International, 2005, 67, 531-542.	2.6	152
24	Short-term Hemodynamic Effects of Immunoadsorption in Dilated Cardiomyopathy. Circulation, 1997, 95, 1994-1997.	1.6	143
25	Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. European Journal of Immunology, 1999, 29, 2908-2915.	1.6	142
26	Autologous Epstein-Barr virus (EBV)–specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood, 2002, 100, 4059-4066.	0.6	141
27	Enzyme-Linked Immunosorbent Spot Assay for Donor-Reactive Interferon-Gamma-Producing Cells Identifies T-Cell Presensitization and Correlates with Graft Function at 6 and 12 Months in Renal-Transplant Recipients. Transplantation, 2004, 78, 1640-1646.	0.5	136
28	A Novel Link between Stress and Human Cytomegalovirus (HCMV) Infection: Sympathetic Hyperactivity Stimulates HCMV Activation. Virology, 2000, 272, 357-365.	1.1	132
29	Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney International, 2006, 69, 1683-1690.	2.6	131
30	TCR Repertoire Analysis by Next Generation Sequencing Allows Complex Differential Diagnosis of T Cell–Related Pathology. American Journal of Transplantation, 2013, 13, 2842-2854.	2.6	131
31	ILâ€15 dependent induction of ILâ€18 secretion as a feedback mechanism controlling human MAITâ€cell effector functions. European Journal of Immunology, 2015, 45, 2286-2298.	1.6	122
32	Regulatory T cell-mediated anti-inflammatory effects promote successful tissue repair in both indirect and direct manners. Frontiers in Pharmacology, 2015, 6, 184.	1.6	122
33	BK Virus-Specific Immunity Kinetics: A Predictor of Recovery From Polyomavirus BK-Associated Nephropathy. American Journal of Transplantation, 2011, 11, 2443-2452.	2.6	121
34	Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transplant Infectious Disease, 1999, 1, 157-164.	0.7	119
35	Circulating Alloreactive T Cells Correlate with Graft Function in Longstanding Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2008, 19, 1419-1429.	3.0	118
36	Donor–Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation. American Journal of Transplantation, 2017, 17, 3076-3086.	2.6	117

#	Article	IF	CITATIONS
37	Overcoming Challenges Facing Advanced Therapies in the EU Market. Cell Stem Cell, 2016, 19, 293-297.	5.2	114
38	Old-for-Old Kidney Allocation Allows Successful Expansion of the Donor and Recipient Pool. American Journal of Transplantation, 2003, 3, 1434-1439.	2.6	111
39	Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study. American Journal of Transplantation, 2015, 15, 119-128.	2.6	109
40	Immunogenicity and Safety of Hepatitis A Vaccine in Liver and Renal Transplant Recipients. Journal of Infectious Diseases, 1999, 180, 2014-2017.	1.9	102
41	Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. International Journal of Cardiology, 1996, 54, 191-195.	0.8	100
42	BK polyomavirus infection and nephropathy: the virus–immune system interplay. Nature Reviews Nephrology, 2011, 7, 399-406.	4.1	100
43	ENHANCED GRANULYSIN mRNA EXPRESSION IN URINARY SEDIMENT IN EARLY AND DELAYED ACUTE RENAL ALLOGRAFT REJECTION. Transplantation, 2004, 77, 1866-1875.	0.5	97
44	RAPID DECLINE OF ANTIBODIES AFTER HEPATITIS A IMMUNIZATION IN LIVER AND RENAL TRANSPLANT RECIPIENTS. Transplantation, 2001, 71, 477-479.	0.5	95
45	Renal Function, Efficacy, and Safety of Sirolimus and Mycophenolate Mofetil After Short-Term Calcineurin Inhibitor-Based Quadruple Therapy in De Novo Renal Transplant Patients: One-Year Analysis of a Randomized Multicenter Trial. Transplantation, 2010, 90, 175-183.	0.5	91
46	Adoptive T-Cell Therapy of a Lung Transplanted Patient with Severe CMV Disease and Resistance to Antiviral Therapy. American Journal of Transplantation, 2009, 9, 1679-1684.	2.6	90
47	Relationship of Immunosuppression to Epstein–Barr Viral Load and Lymphoproliferative Disease in Pediatric Heart Transplant Patients. Journal of Heart and Lung Transplantation, 2008, 27, 100-105.	0.3	88
48	Sustained BK Viruria as an Early Marker for the Development of BKV-Associated Nephropathy: Analysis of 4128 Urine and Serum Samples. Transplantation, 2009, 88, 89-95.	0.5	85
49	Cross-Validation of IFN- $\hat{I}^3$ Elispot Assay for Measuring Alloreactive Memory/Effector T Cell Responses in Renal Transplant Recipients. American Journal of Transplantation, 2013, 13, 1880-1890.	2.6	83
50	Immunoadsorption to remove $\tilde{A}\ddot{\forall}2$ adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS ONE, 2018, 13, e0193672.	1.1	83
51	Analysis of Tumor Necrosis Factor-α, Transforming Growth Factor-β, Interleukin-10, IL-6, and Interferon-γ Gene Polymorphisms in Patients With Chronic Periodontitis. Journal of Periodontology, 2006, 77, 1978-1983.	1.7	82
52	Immunohistochemical Detection of Hypoxia-Inducible Factor- $1\hat{l}\pm$ in Human Renal Allograft Biopsies. Journal of the American Society of Nephrology: JASN, 2007, 18, 343-351.	3.0	82
53	Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome. PLoS ONE, 2014, 9, e85387.	1.1	82
54	Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study. American Journal of Transplantation, 2012, 12, 1528-1540.	2.6	77

#	Article	IF	Citations
55	The Loss of BKV-specific Immunity From Pretransplantation to Posttransplantation Identifies Kidney Transplant Recipients at Increased Risk of BKV Replication. American Journal of Transplantation, 2015, 15, 2159-2169.	2.6	75
56	High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transplant Immunology, 2009, 20, 238-242.	0.6	74
57	ROUTINE IMMUNIZATIONS IN ADULT RENAL TRANSPLANT RECIPIENTS. Transplantation, 1997, 63, 839-845.	0.5	74
58	Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. Transplantation, 2003, 75, 1565-1570.	0.5	72
59	B-Cell-Related Biomarkers of Tolerance are Up-Regulated in Rejection-Free Kidney Transplant Recipients. Transplantation, 2013, 95, 148-154.	0.5	72
60	Salvage Chemotherapy for Refractory and Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) After Treatment With Single-Agent Rituximab. Transplantation, 2007, 83, 912-918.	0.5	70
61	Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. International Journal of Hematology, 2010, 91, 877-885.	0.7	69
62	Identification of Dialysis Patients with Panel-Reactive Memory T Cells before Kidney Transplantation Using an Allogeneic Cell Bank. Journal of the American Society of Nephrology: JASN, 2006, 17, 573-580.	3.0	68
63	Absolute and functional iron deficiency in professional athletes during training and recovery. International Journal of Cardiology, 2012, 156, 186-191.	0.8	68
64	A NOVEL SELECTIVE EXTRACORPOREAL INTERVENTION IN SEPSIS. Shock, 2007, 28, 418-425.	1.0	66
65	Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney International, 2013, 84, 1226-1236.	2.6	66
66	BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study. EBioMedicine, 2018, 34, 113-121.	2.7	66
67	Multi-Parameter Analysis of Biobanked Human Bone Marrow Stromal Cells Shows Little Influence for Donor Age and Mild Comorbidities on Phenotypic and Functional Properties. Frontiers in Immunology, 2019, 10, 2474.	2.2	64
68	Symptomatic lymphoceles after kidney transplantation $\hat{a}\in$ multivariate analysis of risk factors and outcome after laparoscopic fenestration. Clinical Transplantation, 2010, 24, 273-280.	0.8	63
69	Diagnosis and treatment of postâ€transplantation lymphoproliferative disorder in pediatric heart transplant patients. Pediatric Transplantation, 2009, 13, 54-62.	0.5	62
70	Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica, 2011, 96, 1067-1071.	1.7	61
71	Novel GMP-Compatible Protocol Employing an Allogeneic B Cell Bank for Clonal Expansion of Allospecific Natural Regulatory T Cells. American Journal of Transplantation, 2014, 14, 594-606.	2.6	60
72	HLA Type-Independent Method to Monitor Polyoma BK Virus-Specific CD4+and CD8+T-Cell Immunity. American Journal of Transplantation, 2006, 6, 625-631.	2.6	57

#	Article	IF	CITATIONS
73	Fractal Structures in Fullerene Layers:  Simulation of the Growth Process. Journal of Physical Chemistry C, 2008, 112, 4687-4695.	1.5	57
74	Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Cytotherapy, 2013, 15, 362-383.	0.3	57
75	The enigma of CD57+CD28-T cell expansion-anergy or activation?. Clinical and Experimental Immunology, 1996, 104, 180-184.	1.1	56
76	Heightened Expression of the Cytotoxicity Receptor NKG2D Correlates with Acute and Chronic Nephropathy After Kidney Transplantation. American Journal of Transplantation, 2007, 7, 423-433.	2.6	56
77	Sepsis: Time has come to focus on the later stages. Medical Hypotheses, 2008, 71, 203-208.	0.8	56
78	Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies. Intensive Care Medicine, 2001, 27, 987-991.	3.9	55
79	In vivo effect of bone marrow-derived mesenchymal stem cells in a rat kidney transplantation model with prolonged cold ischemia. Transplant International, 2011, 24, 1112-1123.	0.8	55
80	Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. Journal of Hepatology, 2014, 60, 928-933.	1.8	55
81	KIR/HLA Ligand Incompatibility in Kidney Transplantation. Transplantation, 2007, 84, 1527-1533.	0.5	54
82	Immunogenicity of allogeneic mesenchymal stromal cells: what has been seen <i>in vitro</i> and <i>in vivo</i> ?. Regenerative Medicine, 2015, 10, 305-315.	0.8	54
83	Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients. Transplantation, 2018, 102, 876-882.	0.5	53
84	Immunomodulatory placentalâ€expanded, mesenchymal stromal cells improve muscle function following hip arthroplasty. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 880-897.	2.9	53
85	BK-VP3 as a New Target of Cellular Immunity in BK Virus Infection. Transplantation, 2011, 91, 100-107.	0.5	51
86	CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor. Transplantation, 2017, 101, e315-e325.	0.5	49
87	Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1056-1066.	2.2	49
88	Epstein–Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Annals of Hematology, 2006, 85, 478-484.	0.8	48
89	Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transplant Infectious Disease, 2008, 10, 59-62.	0.7	48
90	Long-term Results of Subtotal vs Total Parathyroidectomy Without Autotransplantation in Kidney Transplant Recipients. Archives of Surgery, 2008, 143, 756.	2.3	48

#	Article	IF	Citations
91	Mesenchymal Stromal Cells Prevent Allostimulation In Vivo and Control Checkpoints of Th1 Priming: Migration of Human DC to Lymph Nodes and NK Cell Activation. Stem Cells, 2015, 33, 3087-3099.	1.4	48
92	International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20-Positive B Cell PTLD: Clues From the PTLD-1 Trial. American Journal of Transplantation, 2015, 15, 1091-1100.	2.6	48
93	Current characteristics and outcome of cytomegalovirus infections after kidney transplantation. Transplant Infectious Disease, 2014, 16, 568-577.	0.7	47
94	Evidence for Genetic Susceptibility Towards Development of Posttransplant Lymphoproliferative Disorder in Solid Organ Recipients. Transplantation, 2007, 84, 387-391.	0.5	46
95	Novel Approach for Improved Assessment of Phenotypic and Functional Characteristics of BKV-Specific T-Cell Immunity. Transplantation, 2011, 92, 1269-1277.	0.5	46
96	Modified ELISPOT technique $\hat{a} \in \mathbb{C}^n$ Highly significant inverse correlation of post-Tx donor-reactive IFN $\hat{a}$ -producing cell frequencies with 6 and 12 $\hat{a}$ months graft function in kidney transplant recipients. Transplant Immunology, 2006, 16, 232-237.	0.6	44
97	Treatment of PTLD with Rituximab and CHOP Reduces the Risk of Renal Graft Impairment after Reduction of Immunosuppression. American Journal of Transplantation, 2009, 9, 2331-2337.	2.6	42
98	Immunomodulation by adoptive regulatory Tâ€cell transfer improves Coxsackievirus B3â€induced myocarditis. FASEB Journal, 2018, 32, 6066-6078.	0.2	42
99	Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody–Activated Chimeric Antigen Receptor–Modified T Cells. Journal of Immunology, 2017, 199, 348-362.	0.4	41
100	Alternative Route to Silicene Synthesis via Surface Reconstruction on h-MoSi <sub>2</sub> Crystallites. Nano Letters, 2017, 17, 299-307.	4.5	40
101	Human Cytomegalovirus Reactivation in Bone-Marrow-Derived Granulocyte/Monocyte Progenitor Cells and Mature Monocytes. Intervirology, 1999, 42, 308-313.	1.2	39
102	The Influence of Recovery and Training Phases on Body Composition, Peripheral Vascular Function and Immune System of Professional Soccer Players. PLoS ONE, 2009, 4, e4910.	1.1	39
103	The genetic predisposition of natural killer cell to BK virus–associated nephropathy in renal transplant patients. Kidney International, 2013, 84, 359-365.	2.6	39
104	LATE ACUTE REJECTION IN LONG-TERM RENAL ALLOGRAFT RECIPIENTS. Transplantation, 1994, 58, 35-41.	0.5	39
105	Expansion of Memory-Type CD8+ T Cells Correlates With the Failure of Early Immunosuppression Withdrawal After Cadaver Liver Transplantation Using High-Dose ATG Induction and Rapamycin. Transplantation, 2013, 96, 306-315.	0.5	38
106	Title is missing!. Molecular and Cellular Biochemistry, 2000, 212, 45-50.	1.4	37
107	DELAYED-TYPE HYPERSENSITIVITY-LIKE MECHANISMS DOMINATE LATE ACUTE REJECTION EPISODES IN RENAL ALLOGRAFT RECIPIENTS1,2. Transplantation, 1996, 61, 1233-1240.	0.5	37
108	Thermally induced structural changes in amorphous carbon films observed with ultraviolet photoelectron spectroscopy. Journal of Applied Physics, 1997, 81, 2396-2399.	1.1	36

#	Article	IF	CITATIONS
109	Consider delayed immunosuppression into the concept of sepsis. Critical Care Medicine, 2008, 36, 3118.	0.4	36
110	Cytomegalovirus-Specific Regulatory and Effector T Cells Share TCR Clonality—Possible Relation to Repetitive CMV Infections. American Journal of Transplantation, 2012, 12, 669-681.	2.6	36
111	Peripheral Blood–Derived Virus-Specific Memory Stem T Cells Mature to Functional Effector Memory Subsets with Self-Renewal Potency. Journal of Immunology, 2015, 194, 5559-5567.	0.4	36
112	VEGF – Supplemented extracellular matrix is sufficient to induce endothelial differentiation of human iPSC. Biomaterials, 2019, 216, 119283.	5.7	36
113	CYTOTOXIC EFFECTOR MOLECULE GENE EXPRESSION IN ACUTE RENAL ALLOGRAFT REJECTION. Transplantation, 2001, 72, 1158-1161.	0.5	36
114	Comparative characterization of decellularized renal scaffolds for tissue engineering. Biomedical Materials (Bristol), 2017, 12, 045005.	1.7	35
115	In Operando Analysis of Passive Film Growth on Ni-Cr and Ni-Cr-Mo Alloys in Chloride Solutions. Journal of the Electrochemical Society, 2019, 166, C3241-C3253.	1.3	35
116	Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients. Transplantation Proceedings, 2004, 36, 2679-2682.	0.3	34
117	Salvage Therapy for Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) With a Second Progression of PTLD After Upfront Chemotherapy: The Role of Single-Agent Rituximab. Transplantation, 2007, 84, 1708-1712.	0.5	34
118	Treatment with granulocyte–macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. Scandinavian Journal of Infectious Diseases, 2010, 42, 164-171.	1.5	34
119	HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy. European Journal of Immunology, 2005, 35, 2250-2258.	1.6	33
120	Impaired Insulin Sensitivity as an Underlying Mechanism Linking Hepatitis C and Posttransplant Diabetes Mellitus in Kidney Recipients. American Journal of Transplantation, 2009, 9, 2777-2784.	2.6	33
121	Predicting the outcome of renal transplantation. Journal of the American Medical Informatics Association: JAMIA, 2012, 19, 255-262.	2.2	33
122	Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation. Transplant International, 2014, 27, 290-301.	0.8	33
123	Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clinical Nephrology, 2015, 83 (2015), 11-21.	0.4	33
124	ASSOCIATION BETWEEN EPSTEIN-BARR VIRUS INFECTION AND LATE ACUTE TRANSPLANT REJECTION IN LONG-TERM TRANSPLANT PATIENTS1. Transplantation, 2001, 72, 736-739.	0.5	33
125	Exercise capacity and body composition in living-donor renal transplant recipients over time.  Nephrology Dialysis Transplantation, 2009, 24, 3854-3860.	0.4	32
126	Potent Early Immune Response After Kidney Transplantation in Patients of the European Senior Transplant Program. Transplantation, 2009, 87, 992-1000.	0.5	32

#	Article	IF	CITATIONS
127	Human peripheral blood and bone marrow Epstein–Barr virusâ€specific Tâ€cell repertoire in latent infection reveals distinct memory Tâ€cell subsets. European Journal of Immunology, 2010, 40, 1566-1576.	1.6	32
128	Different risk factor profiles distinguish early-onset from late-onset BKV-replication. Transplant International, 2015, 28, 1081-1091.	0.8	32
129	Putting a price tag on novel autologous cellular therapies. Cytotherapy, 2016, 18, 1056-1061.	0.3	32
130	Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series. European Heart Journal - Case Reports, 2019, 3, .	0.3	32
131	Bio-instructive hydrogel expands the paracrine potency of mesenchymal stem cells. Biofabrication, 2021, 13, 045002.	3.7	32
132	Acute esophageal necrosis (black esophagus) in the renal transplant recipient: manifestation of primary cytomegalovirus infection. Transplant Infectious Disease, 2007, 9, 42-45.	0.7	31
133	Human CD45RAâ^ FoxP3hi Memory-Type Regulatory T Cells Show Distinct TCR Repertoires With Conventional T Cells and Play an Important Role in Controlling Early Immune Activation. American Journal of Transplantation, 2015, 15, 2625-2635.	2.6	31
134	Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. Nephrology Dialysis Transplantation, 2017, 32, 1060-1070.	0.4	31
135	Repassivation Behavior of Individual Grain Facets on Dilute Ni–Cr and Ni–Cr–Mo Alloys in Acidified Chloride Solution. Journal of Physical Chemistry C, 2018, 122, 19499-19513.	1.5	31
136	Measurement of Anti-Human Cytomegalovirus T Cell Reactivity in Transplant Recipients and Its Potential Clinical Use: A Mini-Review. Intervirology, 1999, 42, 322-324.	1.2	30
137	IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment. Transplant International, 2011, 24, 892-903.	0.8	30
138	Prophylaxis of Recurrent Urinary Tract Infection After Renal Transplantation by Cranberry Juice and L-Methionine. Transplantation Proceedings, 2012, 44, 3017-3021.	0.3	30
139	Burkitt postâ€ŧransplantation lymphoma in adult solid organ transplant recipients. Cancer, 2012, 118, 4715-4724.	2.0	29
140	Permanent CNI Treatment for Prevention of Renal Allograft Rejection in Sensitized Hosts Can Be Replaced by Regulatory T Cells. American Journal of Transplantation, 2012, 12, 2384-2394.	2.6	29
141	The role of CD4+ T cells in BKV-specific T cell immunity. Medical Microbiology and Immunology, 2014, 203, 395-408.	2.6	29
142	Treatment of Cytomegalovirus Disease with Valganciclovir in Renal Transplant Recipients: A Single Center Experience. Transplantation, 2004, 78, 283-285.	0.5	28
143	Molecular Phenotypes of Acute Rejection Predict Kidney Graft Prognosis. Journal of the American Society of Nephrology: JASN, 2010, 21, 173-180.	3.0	28
144	The business case for cell and gene therapies. Nature Biotechnology, 2014, 32, 1192-1193.	9.4	28

#	Article	IF	Citations
145	Diagnostic and Predictive Value of an Immune Monitoring Program for Complications after Kidney Transplantation. Urologia Internationalis, 1992, 49, 69-75.	0.6	27
146	Alterations of the immune response with increasing recipient age are associated with reduced long-term organ graft function of rat kidney allografts1. Transplantation, 2003, 76, 1560-1568.	0.5	27
147	Formation of manganese nanostructures on the Si(100)-( $2\tilde{A}$ -1) surface. Surface Science, 2008, 602, 986-992.	0.8	27
148	Monitoring tolerance and rejection in organ transplant recipients. Biomarkers, 2011, 16, S42-S50.	0.9	27
149	The Role of Pre-existing Cross-Reactive Central Memory CD4 T-Cells in Vaccination With Previously Unseen Influenza Strains. Frontiers in Immunology, 2019, 10, 593.	2.2	27
150	Nonimmunologic complications and gene polymorphisms of immunoregulatory cytokines in long-term renal transplants. Kidney International, 2004, 66, 428-432.	2.6	26
151	Can We Use Biomarkers and Functional Assays to Implement Personalized Therapies in Transplantation?. Transplantation, 2009, 87, 1595-1601.	0.5	26
152	End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry. Transplantation, 2018, 102, 868-875.	0.5	26
153	Long-term outcome of ATG vs. Basiliximab induction. European Journal of Clinical Investigation, 2011, 41, 971-978.	1.7	25
154	ABO desensitization affects cellular immunity and infection control after renal transplantation. Transplant International, 2015, 28, 1179-1194.	0.8	25
155	Strain Lattice Imprinting in Graphene by C <sub>60</sub> Intercalation at the Graphene/Cu Interface. Nano Letters, 2015, 15, 7421-7430.	4.5	25
156	A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients. Kidney International, 2015, 88, 1293-1303.	2.6	25
157	Rescue from lethal acute radiation syndrome (ARS) with severe weight loss by secretome of intramuscularly injected human placental stromal cells. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 1079-1092.	2.9	25
158	Thermally Induced Defects on WSe <sub>2</sub> . Journal of Physical Chemistry C, 2020, 124, 15337-15346.	1.5	25
159	Colour-coded duplex sonography in the diagnostic assessment of vascular complications after kidney transplantation in children. Pediatric Radiology, 1997, 27, 898-902.	1.1	24
160	ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. Transplantation Proceedings, 2003, 35, 2100-2101.	0.3	24
161	Rat Cytomegalovirus Infection Interferes with Anti-CD4 mAb-(RIB 5/2) Mediated Tolerance and Induces Chronic Allograft Damage. American Journal of Transplantation, 2006, 6, 2035-2045.	2.6	24
162	Interleukin-6 serum level assessment using a new qualitative point-of-care test in sepsis: A comparison with ELISA measurements. Clinical Biochemistry, 2008, 41, 893-898.	0.8	24

#	Article	IF	CITATIONS
163	Diagnostic value of T-cell monitoring assays in kidney transplantation. Current Opinion in Organ Transplantation, 2009, 14, 426-431.	0.8	24
164	Anti-CD4 therapy of acute rejection in long-term renal allograft recipients. Lancet, The, 1991, 338, 702-703.	6.3	23
165	Whole blood flow cytometric measurement of NFATc1 and ILâ $\in$ 2 expression to analyze cyclosporine Aâ $\in$ mediated effects in T cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 607-613.	1.1	23
166	A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends in Molecular Medicine, 2014, 20, 632-642.	3.5	23
167	Atomic Scale Surface Structure and Morphology of InAs Nanowire Crystal Superlattices: The Effect of Epitaxial Overgrowth. ACS Applied Materials & Samp; Interfaces, 2015, 7, 5748-5755.	4.0	23
168	Prevalence and Clinical Correlates of Chronic Hepatitis E Infection in German Renal Transplant Recipients With Elevated Liver Enzymes. Transplantation Direct, 2018, 4, e341.	0.8	23
169	From Alloy to Oxide: Capturing the Early Stages of Oxidation on Ni–Cr(100) Alloys. ACS Applied Materials & Capturing the Early Stages of Oxidation on Ni–Cr(100) Alloys. ACS Applied Materials & Capturing the Early Stages of Oxidation on Ni–Cr(100) Alloys. ACS Applied Materials & Capturing the Early Stages of Oxidation on Ni–Cr(100) Alloys. ACS Applied Materials & Capturing the Early Stages of Oxidation on Ni–Cr(100) Alloys. ACS Applied Materials & Capturing the Early Stages of Oxidation on Ni–Cr(100) Alloys. ACS Applied Materials & Capturing the Early Stages of Oxidation on Ni–Cr(100) Alloys. ACS Applied Materials & Capturing the Early Stages of Oxidation on Ni–Cr(100) Alloys. ACS Applied Materials & Capturing the Early Stages of Oxidation on Ni–Cr(100) Alloys. ACS Applied Materials & Capturing the Early Stages of Oxidation on Ni–Cr(100) Alloys. ACS Applied Materials & Capturing the Early Stages of Oxidation on Ni—Cr(100) Alloys. ACS Applied Materials & Capturing the Early Stages of Oxidation on Ni—Cr(100) Alloys. ACS Applied Materials & Capturing the Early Stages of Oxidation on Ni—Cr(100) Alloys. ACS Applied Materials & Capturing the Early Stages of Oxidation on Ni†"Cr(100) Alloys." Account the Early Stages of Oxidation on Ni†"Cr(100) Alloys." Account the Early Stages of Oxidation on Ni†"Cr(100) Alloys." Account the Early Stages of Oxidation on Ni†"Cr(100) Alloys." Account the Early Stages of Oxidation on Ni†"Cr(100) Alloys." Account the Early Stages of Oxidation on Ni†"Cr(100) Alloys." Account the Early Stages of Oxidation on Ni†"Cr(100) Alloys." Account the Early Stages of Oxidation on Ni†"Cr(100) Alloys" Account the Early Stages of Oxidation on Ni†"Cr(100)" Alloys. Account the Early Stages of Oxidation on Ni†"Cr(100)" Alloys (Capturing the Early Stages of Oxidation on Ni†"Cr(100)" Alloys (Capturing the Early Stages of Oxidation on Niâ§ "Cr(100)" Alloys (Capturing the Early Stages of Oxidation on Niâ§ "Cr(100)" Alloys (Capturing the Early Stages on Niâ§ "Cr(10	4.0	23
170	Generation of HCMV-specific T-cell Lines From Seropositive Solid-organ-transplant Recipients for Adoptive T-cell Therapy. Journal of Immunotherapy, 2009, 32, 932-940.	1.2	22
171	Preferential Expansion of Human Virus-Specific Multifunctional Central Memory T Cells by Partial Targeting of the IL-2 Receptor Signaling Pathway: The Key Role of CD4+ T Cells. Journal of Immunology, 2012, 188, 5189-5198.	0.4	22
172	Comparing Humoral and Cellular Immune Response Against HBV Vaccine in Kidney Transplant Patients. American Journal of Transplantation, 2015, 15, 3157-3165.	2.6	22
173	Pretransplant prophylactic rituximab to prevent Epsteinâ€Barr virus ( <scp>EBV</scp> ) viremia in <scp>EBV</scp> â€seronegative kidney transplant recipients from <scp>EBV</scp> â€seropositive donors: results of a pilot study. Transplant Infectious Disease, 2016, 18, 881-888.	0.7	22
174	Sepsis after renal transplantation: Clinical, immunological, and microbiological risk factors. Transplant Infectious Disease, 2017, 19, e12695.	0.7	22
175	Discordant Expression of LFA-1 VLA-4α, VLA-β1, CD45RO and CD28 on T-Cell Subsets: Evidence for Multiple Subsets of †Memory' T Cells. International Archives of Allergy and Immunology, 1994, 104, 17-26.	0.9	21
176	Clonotype Analysis of Cytomegalovirus-Specific Cytotoxic T Lymphocytes. Journal of the American Society of Nephrology: JASN, 2009, 20, 344-352.	3.0	21
177	Nanoscale probing of electronic band gap and topography of VO2 thin film surfaces by scanning tunneling microscopy. Journal of Applied Physics, 2011, 109, .	1.1	21
178	Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients. Transplant International, 2012, 25, 680-686.	0.8	21
179	Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients. Medical Microbiology and Immunology, 2014, 203, 35-45.	2.6	21
180	Estimated nephron number of the remaining donor kidney: impact on living kidney donor outcomes. Nephrology Dialysis Transplantation, 2016, 31, 1523-1530.	0.4	21

#	Article	IF	CITATIONS
181	Abnormalities of Pulmonary Diffusion Capacity in Long-term Survivors After Kidney Transplantation. Chest, 2002, 122, 639-644.	0.4	20
182	Impaired thymic function and CD4+ T lymphopenia, but not mannose-binding lectin deficiency, are risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients. Transplant Immunology, 2013, 28, 159-163.	0.6	20
183	Generation of integration free induced pluripotent stem cells from fibrodysplasia ossificans progressiva (FOP) patients from urine samples. Stem Cell Research, 2016, 16, 54-58.	0.3	20
184	ExÂvivo expanded natural regulatory T cells from patients with end-stage renal disease or kidney transplantation are useful for autologous cell therapy. Kidney International, 2018, 93, 1452-1464.	2.6	20
185	Heterologous Cytomegalovirus and Allo-Reactivity by Shared T Cell Receptor Repertoire in Kidney Transplantation. Frontiers in Immunology, 2019, 10, 2549.	2.2	20
186	Cytomegalovirus infection and common variable immunodeficiency. Lancet, The, 1991, 338, 1597.	6.3	19
187	Induction of heme-oxygenase-1 prevents ischemia/reperfusion injury and improves long-term graft outcome in rat renal allografts. Transplantation Proceedings, 2001, 33, 1286-1287.	0.3	19
188	CD31+ Naive Th Cells Are Stable during Six Months Following Kidney Transplantation: Implications for Post-transplant Thymic Function. American Journal of Transplantation, 2005, 5, 1764-1771.	2.6	19
189	Accelerating Patients' Access to Advanced Therapies in the EU. Molecular Therapy - Methods and Clinical Development, 2017, 7, 15-19.	1.8	19
190	Ge1 $\hat{a}$ °'xMnx heteroepitaxial quantum dots: Growth, morphology, and magnetism. Journal of Applied Physics, 2013, 113, .	1.1	18
191	Clindamycin–primaquine for pneumocystis jiroveci pneumonia in renal transplant patients. Infection, 2014, 42, 981-989.	2.3	18
192	Evaluation of adherence and tolerability of prolongedâ€release tacrolimus (Advagrafâ,,¢) in kidney transplant patients in Germany: A multicenter, noninterventional study. Clinical Transplantation, 2018, 32, e13142.	0.8	18
193	BKV Clearance Time Correlates With Exhaustion State and T-Cell Receptor Repertoire Shape of BKV-Specific T-Cells in Renal Transplant Patients. Frontiers in Immunology, 2019, 10, 767.	2.2	18
194	T Cell Response to the Cytomegalovirus Major Capsid Protein (UL86) Is Dominated by Helper Cells with a Large Polyfunctional Component and Diverse Epitope Recognition. Journal of Infectious Diseases, 2008, 197, 1455-1458.	1.9	17
195	Industry–academia collaborations for biomarkers. Nature Reviews Drug Discovery, 2015, 14, 805-806.	21.5	17
196	The growth of manganese layers on Si(100) at room temperature: A photoelectron spectroscopy study. Applied Surface Science, 2009, 255, 7642-7646.	3.1	16
197	Floating two-dimensional solid monolayer of <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:mrow> <mml:msub> <mml:mtext> C </mml:mtext> <mml:mrow> <mml:mn> 60 </mml:mn> <td>n<mark>1.1</mark> nml:mrow</td><td>, &gt;<b><!--</b-->mml:ms</b></td></mml:mrow></mml:msub></mml:mrow></mml:math>	n <mark>1.1</mark> nml:mrow	, > <b><!--</b-->mml:ms</b>
198	Renal function to 5Âyears after late conversion of kidney transplant patients to everolimus: a randomized trial. Journal of Nephrology, 2015, 28, 115-123.	0.9	16

#	Article	IF	CITATIONS
199	Reduction of Gastrointestinal Complications in Renal Graft Recipients after Conversion from Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium. Transplantation Proceedings, 2011, 43, 1641-1646.	0.3	15
200	Bonding geometry of Mn-wires on the Si(100)(2 $\tilde{A}$ — 1) surface. Surface Science, 2011, 605, L29-L32.	0.8	15
201	HCMV-specific T-cell Therapy. Journal of Immunotherapy, 2013, 36, 93-101.	1.2	15
202	Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation. Nephrology Dialysis Transplantation, 2017, 32, 880-889.	0.4	15
203	Intensive blood pressure control is associated with improved patient and graft survival after renal transplantation. Scientific Reports, 2019, 9, 10507.	1.6	15
204	Parallel generation of easily selectable multiple nephronal cell types from human pluripotent stem cells. Cellular and Molecular Life Sciences, 2019, 76, 179-192.	2.4	15
205	Living Kidney Donation: Anemia and Inflammation in the Early Postoperative Period. Transplantation Proceedings, 2006, 38, 661-663.	0.3	14
206	Pretransplant immune risk assessment. Current Opinion in Organ Transplantation, 2009, 14, 650-655.	0.8	14
207	Manganese Nanostructures on Si(100)(2 $\tilde{A}$ — 1) Surfaces: Temperature-Driven Transition from Wires to Silicides. Journal of Physical Chemistry C, 2010, 114, 19727-19733.	1.5	14
208	Simultaneous pancreas/kidney transplant recipients present with late-onset BK polyomavirus-associated nephropathy. Nephrology Dialysis Transplantation, 2016, 31, 1174-1182.	0.4	14
209	Virus-specific T-cell therapy in solid organ transplantation. Transplant International, 2016, 29, 515-526.	0.8	14
210	Clinical Development of Cell Therapies: Setting the Stage for Academic Success. Clinical Pharmacology and Therapeutics, 2017, 101, 35-38.	2.3	14
211	Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. BMC Nephrology, 2018, 19, 237.	0.8	14
212	A novel approach reveals that HLA class $1$ single antigen bead-signatures provide a means of high-accuracy pre-transplant risk assessment of acute cellular rejection in renal transplantation. BMC Immunology, 2019, 20, 11.	0.9	14
213	The concept of the "Perisinusoidal Functional Unit―of the liver — importance to pathological processes. Experimental Pathology, 1987, 32, 193-224.	0.5	13
214	Generation of EBV-specific T Cells for Adoptive Immunotherapy: A Novel Protocol Using Formalin-fixed Stimulator Cells to Increase Biosafety. Journal of Immunotherapy, 2007, 30, 817-824.	1.2	13
215	Immunization of liver and renal transplant recipients: a seroepidemiological and sociodemographic survey. Transplant Infectious Disease, 2009, 11, 507-512.	0.7	13
216	Lymphocyte markers and prediction of long-term renal allograft acceptance. Current Opinion in Nephrology and Hypertension, 2009, 18, 489-494.	1.0	13

#	Article	IF	CITATIONS
217	State of the art on the research for biomarkers allowing individual, tailor-made minimization of immunosuppression. Current Opinion in Organ Transplantation, 2010, 15, 691-696.	0.8	13
218	Percutaneous Computer Tomography-Guided Ethanol Sympathicolysis for the Treatment of Resistant Arterial Hypertension. CardioVascular and Interventional Radiology, 2014, 37, 513-518.	0.9	13
219	T Cell PTLD Successfully Treated With Single-Agent Brentuximab Vedotin First-Line Therapy. Transplantation, 2016, 100, e8-e10.	0.5	13
220	Evolution of NiO Island Size Distributions during the Oxidation of a Ni–5Cr Alloy: Experiment and Modeling. ACS Applied Materials & Samp; Interfaces, 2018, 10, 9136-9146.	4.0	13
221	Differential T cell response against BK virus regulatory and structural antigens: A viral dynamics modelling approach. PLoS Computational Biology, 2018, 14, e1005998.	1.5	13
222	Short-Term Anti-CD4 Plus Anti-TNF-α Receptor Treatment in Allogeneic Small Bowel Transplantation Results in Long-Term Survival. Transplantation, 2007, 84, 639-646.	0.5	12
223	Human Bone Marrow as a Source to Generate CMV-specific CD4+ T Cells With Multifunctional Capacity. Journal of Immunotherapy, 2009, 32, 907-913.	1.2	12
224	Guided Self-Assembly of Mn Wires on the Si(100)(2 $\tilde{A}$ — 1) Surface. Journal of Physical Chemistry C, 2012, 116, 1670-1678.	1.5	12
225	Transplantectomy is associated with presensitization with donor-reactive T cells and graft failure after kidney retransplantation: a cohort study. Nephrology Dialysis Transplantation, 2018, 33, 889-896.	0.4	12
226	The Identity Card of T Cellsâ€"Clinical Utility of T-cell Receptor Repertoire Analysis in Transplantation. Transplantation, 2019, 103, 1544-1555.	0.5	12
227	Data-driven assessment of chemical vapor deposition grown MoS2 monolayer thin films. Journal of Applied Physics, 2020, 128, .	1.1	12
228	INTRAGRAFT OVEREXPRESSION OF INTERLEUKIN-4 IS NEITHER SUFFICIENT NOR ESSENTIAL FOR TOLERANCE INDUCTION TO CARDIAC ALLOGRAFTS IN A HIGH-RESPONDER STRAIN COMBINATION1. Transplantation, 1999, 68, 1427-1431.	0.5	12
229	Malignant Tumours after Renal Transplantation. Scandinavian Journal of Urology and Nephrology, 1996, 30, 357-362.	1.4	11
230	Improvement of long-term function in renal allografts from â€~marginal donors' following the induction of heme-oxygenase-1. Transplantation Proceedings, 2001, 33, 1160-1161.	0.3	11
231	TIRC7 is induced in rejected human kidneys and anti-TIRC7 mAb with FK506 prolongs survival of kidney allografts in rats. Transplant Immunology, 2006, 16, 238-244.	0.6	11
232	BCRâ€ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients. European Journal of Haematology, 2010, 84, 26-33.	1.1	11
233	Inkjet printing on transparency films for reagent storage with polyester–toner microdevices. Analytical Methods, 2016, 8, 7061-7068.	1.3	11
234	Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. American Journal of Transplantation, 2018, 18, 2965-2976.	2.6	11

#	Article	IF	Citations
235	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. Transplantation, 2018, 102, 1914-1923.	0.5	11
236	Effects of Treatment of Asymptomatic Hyperuricemia on Graft Survival and Mortality in Kidney Transplant Recipients. Annals of Transplantation, 2016, 21, 350-359.	0.5	11
237	Sequential Targeting of CD52 and TNF Allows Early Minimization Therapy in Kidney Transplantation: From a Biomarker to Targeting in a Proof-Of-Concept Trial. PLoS ONE, 2017, 12, e0169624.	1.1	10
238	Pathology of hepatic peroxisomes in chronic hepatitis B and immunosuppression. Experimental Pathology, 1988, 34, 71-77.	0.5	9
239	Selective in vivo deletion of alloactivated TH1 cells by OKT3 monoclonal antibody in acute rejection. Immunology Letters, 1997, 57, 151-153.	1.1	9
240	Influence of erbium on the electronic structure of Fe( $65\hat{a}^{\circ}$ x)Mo14C15B6Erx (x=0,1,2) bulk metallic glasses. Journal of Applied Physics, 2009, 105, 023518.	1.1	9
241	Mannose-binding lectin deficiency is not associated with increased risk for polyomavirus nephropathy. Transplant Immunology, 2012, 26, 123-127.	0.6	9
242	Interaction of C <sub>60</sub> with Tungsten: Modulation of Morphology and Electronic Structure on the Molecular Length Scale. Journal of Physical Chemistry C, 2014, 118, 24479-24489.	1.5	9
243	Generation of a human induced pluripotent stem cell line from urinary cells of a healthy donor using an integration free vector. Stem Cell Research, 2016, 16, 314-317.	0.3	9
244	Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients. Frontiers in Immunology, 2019, 10, 1148.	2.2	9
245	Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial. Clinical Nephrology, 2016, 85 (2016), 215-225.	0.4	9
246	Atomic-scale probing of defect-assisted Ga intercalation through graphene using ReaxFF molecular dynamics simulations. Carbon, 2022, 190, 276-290.	5.4	9
247	Gene therapy: a possible future standard for HIV care. Trends in Biotechnology, 2015, 33, 374-376.	4.9	8
248	Increased alloreactivity and adverse outcomes in obese kidney transplant recipients are limited to those with diabetes mellitus. Transplant Immunology, 2017, 40, 8-16.	0.6	8
249	Diabetic kidney transplant recipients: Impaired infection control and increased alloreactivity. Clinical Transplantation, 2017, 31, e12986.	0.8	8
250	Influence of Chloride on Nanoscale Electrochemical Passivation Processes. Journal of Physical Chemistry C, 2020, 124, 9289-9304.	1.5	8
251	Initial atomic-scale oxidation pathways on a Ni–15Cr(100) alloy surface. Npj Materials Degradation, 2021, 5, .	2.6	8
252	Correlating surface stoichiometry and termination in SrTiO3 films grown by hybrid molecular beam epitaxy. Journal of Vacuum Science and Technology A: Vacuum, Surfaces and Films, 2021, 39, .	0.9	8

#	Article	IF	Citations
253	Synergism of CTLA4-IG and anti-CD4 monoclonal antibody treatment in a rat kidney transplant model. Transplantation Proceedings, 1997, 29, 1307-1309.	0.3	7
254	Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases. Transplant Infectious Disease, 2005, 7, 133-136.	0.7	7
255	Kidney transplant recipients after nonrenal solid organ transplantation show low alloreactivity but an increased risk of infection. Transplant International, 2016, 29, 1296-1306.	0.8	7
256	Simultaneous pancreas/kidney transplant recipients are predisposed to tissueâ€invasive cytomegalovirus disease and concomitant infectious complications. Transplant Infectious Disease, 2017, 19, e12742.	0.7	7
257	Estimated Nephron Number of the Donor Kidney: Impact on Allograft Kidney Outcomes. Transplantation Proceedings, 2017, 49, 1237-1243.	0.3	7
258	Cyclosporine use and male gender are independent determinants of avascular necrosis after kidney transplantation: a cohort study. Nephrology Dialysis Transplantation, 2018, 33, 2060-2066.	0.4	7
259	HLA-DR-Expression auf Monozyten bei Peritonitis und Sepsis & 2 amp; ndash; M& 2 amp; ouml; glichkeiten eines therapeutischen Ansatzes. Chirurgische Gastroenterologie Interdisziplinar, 1995, 11, 34-41.	0.0	6
260	Late acute rejection in renal allograft recipients is mediated by inflammatory rather than by cytotoxic T-cell-dependent mechanisms. Transplantation Proceedings, 1997, 29, 93-95.	0.3	6
261	FTY720 Prevents Anti-CD4 mAb-Induced Tolerance but Cannot Reverse Established Tolerance in a Rat Kidney Transplantation Model. American Journal of Transplantation, 2004, 4, 863-871.	2.6	6
262	Accurate Prediction of Kidney Allograft Outcome Based on Creatinine Course in the First 6 Months Posttransplant. Transplantation Proceedings, 2005, 37, 731-733.	0.3	6
263	To be, or not to be immunocompetent. Critical Care, 2013, 17, 185.	2.5	6
264	Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study. Transplant International, 2014, 27, 1192-1204.	0.8	6
265	Effects of expanded allocation programmes and organ and recipient quality metrics on transplantâ€related costs in kidney transplantation – an institutional analysis. Transplant International, 2019, 32, 1074-1084.	0.8	6
266	Reaction pathways in the oxidation and pesting of molybdenum disilicide MoSi2 studied with scanning tunneling microscopy and spectroscopy. Surface Science, 2019, 681, 134-142.	0.8	6
267	High-Mobility Group Box-1 Protein Serum Levels Do Not Reflect Monocytic Function in Patients with Sepsis-Induced Immunosuppression. Mediators of Inflammation, 2010, 2010, 1-6.	1.4	5
268	Molecular Analysis of Renal Allograft Biopsiesâ€"More Than a Nice Toy for Researchers?. American Journal of Transplantation, 2013, 13, 539-540.	2.6	5
269	Electronic Structure and Band Gap of Fullerenes on Tungsten Surfaces: Transition from a Semiconductor to a Metal Triggered by Annealing. ACS Applied Materials & Samp; Interfaces, 2016, 8, 34854-34862.	4.0	5
270	Growth of Ni and Ni-Cr alloy thin films on MgO(001): Effect of alloy composition on surface morphology. Journal of Applied Physics, 2016, 120, 225302.	1.1	5

#	Article	IF	CITATIONS
271	Factors and outcomes in association with sepsis differ between simultaneous pancreas/kidney and single kidney transplant recipients. Transplant Infectious Disease, 2018, 20, e12848.	0.7	5
272	Generating Multiple Kidney Progenitors and Cell Types from Human Pluripotent Stem Cells. Methods in Molecular Biology, 2019, 1926, 103-115.	0.4	5
273	Cytotoxic Effects of Rabbit Anti-thymocyte Globulin Preparations on Primary Human Thymic Epithelial Cells. Transplantation, 2019, 103, 2234-2244.	0.5	5
274	Preformed donorâ€reactive T cells that persist after ABO desensitization predict severe T cellâ€mediated rejection after living donor kidney transplantation – a retrospective study. Transplant International, 2020, 33, 288-297.	0.8	5
275	Editorial comment: variables affecting the presence of mesenchymal stromal cells in the peripheral blood and their relationship with apheresis product. British Journal of Haematology, 2020, 189, 593-596.	1.2	5
276	Unraveling the role of tungsten as a minor alloying element in the oxidation NiCr alloys. Npj Materials Degradation, 2022, $6$ , .	2.6	5
277	Intravenous injection of India ink with suicidal intent. International Journal of Legal Medicine, 1998, 111, 91-92.	1.2	4
278	Risk Stratification for Renal Transplantation after Cardiac or Lung Transplantation: Single-Center Experience and Review of the Literature. Kidney and Blood Pressure Research, 2007, 30, 260-266.	0.9	4
279	Heme Oxygenase-1 Polymorphisms and Renal Transplantation Outcomes: Balancing at the Detection Limit of Allelic Association Studies. American Journal of Transplantation, 2008, 8, 1077-1078.	2.6	4
280	Vitamin A metabolism is changed in donors after living-kidney transplantation: an observational study. Lipids in Health and Disease, 2011, 10, 231.	1.2	4
281	Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial. Leukemia, 2013, 27, 2102-2105.	3.3	4
282	Towards a Mn–Co surface alloy: Scanning Tunneling Microscopy (STM) study of Co adsorption on Si(100) and its interaction with Mn wires. Surface Science, 2014, 620, 1-8.	0.8	4
283	Vasodilation and Exercise Capacity in Patients with End-Stage Renal Disease: A Prospective Proof-of-Concept Study. CardioRenal Medicine, 2017, 7, 50-59.	0.7	4
284	Generation of a human induced pluripotent stem cell line from urinary cells of a healthy donor using integration free Sendai virus technology. Stem Cell Research, 2017, 21, 167-170.	0.3	4
285	Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology, 1996, 24, 751-758.	3.6	4
286	Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine. Transplant International, 1999, 12, 283-287.	0.8	4
287	Kaletra® Single Agent HAART after Intolerance of NRTI- and NNRTI-Containing Regimens Following Kidney Transplantation. Infection, 2007, 35, 194-196.	2.3	3
288	Culture surface influence on T-cell phenotype and function. Clinical Hemorheology and Microcirculation, 2013, 55, 501-512.	0.9	3

#	Article	IF	CITATIONS
289	Fc < b > <i> <math>\hat{l}^3</math> &lt; /i &gt; -Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder. Journal of Immunology Research, 2014, 2014, 1-6.</i>	0.9	3
290	Three-dimensional nanostructures on $Ge/Si(100)$ wetting layers: Hillocks and pre-quantum dots. Journal of Applied Physics, 2016, 119, 205305.	1.1	3
291	Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. BMC Nephrology, 2018, 19, 154.	0.8	3
292	The Value of a Rapid Test of Human Regulatory T Cell Function Needs to be Revised. Frontiers in Immunology, 2019, 10, 150.	2.2	3
293	Intramuscular and intratendinous placentaâ€derived mesenchymal stromalâ€like cell treatment of a chronic quadriceps tendon rupture. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 434-442.	2.9	3
294	The perisinusoidal functional unit in amyloidosis. Experimental Pathology, 1987, 32, 153-162.	0.5	2
295	Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet, The, 1995, 345, 794.	6.3	2
296	Association between the accumulation of hepatitis B virus core gene deletion mutants and progression of liver disease in long-term renal transplant patients. Transplantation Proceedings, 1997, 29, 815-816.	0.3	2
297	Fullerene Nanostructures on Defect-Rich Graphite Surfaces. Journal of Physical Chemistry C, 2009, 113, 8107-8111.	1.5	2
298	Invited letter in response to "Predicted indirectly recognizable HLA epitopes (PIRCHE): Only the tip of the iceberg?â€. American Journal of Transplantation, 2018, 18, 523-524.	2.6	2
299	Electron microscopy of liver in patients with chronic haemodialysis. Experimental Pathology, 1991, 42, 65-75.	0.5	1
300	Reticulocytes and Their Immature Fraction Do Not Detect Acute Rejection After Kidney Transplantation. Transplantation Proceedings, 2007, 39, 514-517.	0.3	1
301	Thermally induced reactions of monolayer WS2 with Au-Ti substrates. Applied Surface Science, 2021, 542, 148576.	3.1	1
302	Tilting in coronene layers on Au(111). Physical Chemistry Chemical Physics, 2020, 22, 26972-26981.	1.3	1
303	Defects in transition metal dichalcogenides. , 2022, , 89-117.		1
304	Cytomegalovirus infections in kidney transplant patients. Transplantation Reviews, 2002, 16, 121-130.	1.2	0
305	Reply to: 'BKV replication and cellular immune response in renal transplant recipients'. American Journal of Transplantation, 2006, 6, 2220-2220.	2.6	0
306	Hierarchical Assembly of 2D Nanostructures of Relevance for Organic Solar Cell Design. Materials Research Society Symposia Proceedings, 2007, 1031, 1.	0.1	0

#	Article	IF	CITATIONS
307	Risk management after cardiopulmonary resuscitationâ€"What is the real threat?. Critical Care Medicine, 2008, 36, 3130-3131.	0.4	0
308	Ge <inf>1−x</inf> Mn <inf>x</inf> heteroepitaxial quantum dots: Growth, structure and magnetism. , 2011, , .		0
309	Silicide formation during Mn doping of Ge/Si (001) self-assembled quantum dots. Journal of Materials Research, 2013, 28, 3210-3217.	1.2	0
310	Magnetic doping of Ge-quantum dots: growth studies exploring the feasibility of modulating QD properties. Proceedings of SPIE, 2014, , .	0.8	0
311	Magnetism in Mn-nanowires and -clusters as $\hat{l}$ -doped layers in group IV semiconductors (Si, Ge). APL Materials, 2018, 6, .	2.2	0
312	Nanostrukturen und OberflÄ <b>e</b> hen: Physik bei atomarer AuflĶsung. , 2019, , 153-162.		0
313	Nierenfunktion, Wirksamkeit und Sicherheit nach sp $\tilde{A}^{\text{te}}$ r Umstellung von Calcineurininhibitoren auf Everolimus bei Patienten nach Nierentransplantation: die randomisierte APOLLO-Studie. Nieren- Und Hochdruckkrankheiten, 2016, 45, 145-156.	0.0	0
314	Fr $\tilde{A}^{1}\!\!/4$ he Umstellung von Cyclosporin auf Everolimus nach Lebendnierentransplantation: 5 Jahresdaten der randomisierten ZEUS Studie. Nieren- Und Hochdruckkrankheiten, 2017, 46, 105-117.	0.0	0